What are the clinical indications for prescribing low-dose aspirin (81 mg acetylsalicylic acid) daily?

Clinical Indications for Low-Dose Aspirin (81 mg) Daily

A patient taking ASA 81 mg daily is most commonly using it for secondary prevention of cardiovascular events after established atherosclerotic cardiovascular disease (ASCVD), including prior myocardial infarction, stroke, coronary artery disease, or peripheral artery disease. 1, 2

Primary Clinical Indications

Secondary Prevention (Most Common)

Low-dose aspirin (75-100 mg daily) is definitively recommended for all patients with established ASCVD unless contraindicated. 1, 2 This includes:

• Post-acute coronary syndrome (ACS): Following STEMI or NSTE-ACS, aspirin 75-100 mg daily is the standard maintenance dose after initial loading 1
• Prior myocardial infarction: Lifelong therapy reduces recurrent cardiovascular events 2
• Coronary artery disease: Including post-PCI or post-CABG patients 2
• Prior ischemic stroke or TIA: Aspirin 81-325 mg daily prevents recurrent cerebrovascular events 2, 3, 2
• Symptomatic peripheral artery disease: Aspirin 75-325 mg daily is recommended 2

Primary Prevention (More Selective)

For primary prevention, aspirin use has become increasingly restricted due to bleeding risks that often outweigh benefits. 4 Current 2019 ACC/AHA guidelines recommend:

• May consider in select adults 40-70 years old at higher ASCVD risk but NOT at increased bleeding risk 4
• Should NOT be used routinely in adults >70 years old (increased bleeding risk outweighs benefit) 4
• Should NOT be used in anyone at increased bleeding risk regardless of age 4

Diabetes-Specific Considerations

In patients with diabetes, aspirin is recommended primarily for secondary prevention, not routine primary prevention. 5, 6, 7 The optimal dose is 75-162 mg daily 5. Aspirin is NOT recommended for:

• Low-risk patients (age <50 years with no other major ASCVD risk factors) 5
• Patients with diabetes alone without established ASCVD 8

Dosing Rationale

The 81 mg dose represents the lowest effective dose that fully inhibits platelet thromboxane A2 production while minimizing bleeding complications. 1 Key evidence:

• The 2025 ACC/AHA guidelines specifically recommend 75-100 mg daily for maintenance therapy, noting this exceeds the minimal effective dose while allowing for interindividual variability 1
• The ADAPTABLE trial (38% diabetes patients) showed no difference in cardiovascular events or major bleeding between 81 mg and 325 mg daily, supporting use of the lower dose 5, 6
• Higher doses (300-325 mg) increase minor and gastrointestinal bleeding without improving efficacy 1

Common Pitfalls to Avoid

1. Enteric-coated formulations: Plain (non-enteric coated) aspirin should be preferred as some patients show poor responsiveness to enteric-coated preparations 1, 9

2. Age considerations: Do not prescribe aspirin for primary prevention in patients >70 years old due to unfavorable risk-benefit ratio 4

3. Bleeding risk assessment: Always evaluate for increased bleeding risk (history of GI bleeding, concurrent anticoagulation, thrombocytopenia) before initiating therapy 4

4. Pediatric use: Aspirin is contraindicated in patients <21 years old due to Reye syndrome risk 5, 6

5. Combination with anticoagulation: When warfarin or other anticoagulants are required (atrial fibrillation, prosthetic valve), use the lowest aspirin dose (75-81 mg daily) and monitor closely for bleeding 2

Dual Antiplatelet Therapy Context

If the patient recently had ACS or PCI with stenting, they should be on dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for a defined period. 1 After this period (typically 12 months), they continue aspirin 81 mg alone indefinitely 1, 2.